These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32787337)

  • 61. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease.
    Ghosh S; Bhattacherjee D; Satpati P; Bhabak KP
    J Biomol Struct Dyn; 2022; 40(22):12088-12099. PubMed ID: 34424151
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).
    Jia Z; Song X; Shi J; Wang W; He K
    Pathog Dis; 2020 Jun; 78(4):. PubMed ID: 32667665
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
    Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
    Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Repurposing of anisomycin and oleandomycin as a potential anti-(SARS-CoV-2) virus targeting key enzymes using virtual computational approaches.
    Zrieq R; Snoussi M; Algahtan FD; Tasleem M; Saeed M; Noumi E; Khalifa NE; Gad-Elkareem MAM; Aouadi K; Kadri A
    Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):387-398. PubMed ID: 35818229
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
    Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
    Deshpande RR; Tiwari AP; Nyayanit N; Modak M
    Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M
    Khan AM; Atia-Tul-Wahab ; Farooq S; Ullah A; Choudhary MI
    Int J Biol Macromol; 2023 Apr; 234():123540. PubMed ID: 36740128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.